Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · IEX Real-Time Price · USD
5.96
-0.31 (-4.94%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
88
Market Cap
228.74M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 8.09M | -5.53M | -40.57% |
Dec 31, 2021 | 13.62M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Akebia Therapeutics | 187.23M |
Codexis | 74.23M |
NeuroPace | 69.07M |
uniQure | 19.00M |
Century Therapeutics | 1.37M |
Q32 Bio | 354.00K |
Atai Life Sciences | 277.00K |
Actinium Pharmaceuticals | 81.00K |
SLDB News
- 1 day ago - Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results - GlobeNewsWire
- 3 months ago - Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 - GlobeNewsWire
- 3 months ago - Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results - GlobeNewsWire
- 6 months ago - Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 - GlobeNewsWire
- 6 months ago - Solid Biosciences Announces $109 Million Private Placement - GlobeNewsWire
- 7 months ago - Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference - GlobeNewsWire